Opinion on R&D

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
Expert View
Expert View

A battle looms in mild cognitive impairment...

More than a tenth of the world's elderly people have mild cognitive impairment, representing a significant potential market. Worse, these sufferers have a 50% chance developing Alzheimer's. Although there is no approved treatment available yet, several different therapies are in development. The fight for dominance in this potentially lucrative market is about to begin - but who will win out?

Published By Datamonitor
07 Dec 2001
Expert View
Expert View

A new phase in the breast cancer battle?

Published By Datamonitor
21 Sep 2001
CommentWire
CommentWire

Abgenix: a new trial for promising cancer drug

Abgenix's drug could have a promising future. If the compound can improve upon the side effect profile of Roche/Genentech's benchmark monoclonal antibody Herceptin (trastuzumab), as well as gaining further indications, it is likely to become a key player within this field of anticancer treatments.

Published By Datamonitor
07 Jan 2002
CommentWire
CommentWire

Actelion: Tracleer approved for pulmonary hypertension

As the first approved oral medication for PAH, the new drug is likely to be popular among treating physicians and enjoy a rapid uptake. However, while Tracleer may improve patients' symptoms, it is a far cry from a cure for PAH, leaving an effective treatment for PAH a major unmet need in the cardiovascular therapeutics market.

Published By Datamonitor
21 Nov 2001
Expert View
Expert View

Acute respiratory distress syndrome: searching for effective therapies

Acute respiratory distress syndrome has an annual incidence of up to 75 cases per 100,000 in the US. The condition remains very difficult to treat with a mortality rate between 30% and 60%. Although much research into ARDS has been carried out, the lack of a standard definition for the condition has made trial results unclear, so what hope is there of a treatment breakthrough in the near future?

Published By Datamonitor
23 Aug 2002
Expert View
Expert View

AIDS: complacency could cause a crisis

Over 50 million people are infected with HIV and the figure is still rising, according to UNAIDS. However, under 30s are continuing to live ignorant of the threat, as a new generation of teenagers has grown up believing that HIV is not something that will affect them. With no cure in sight the Western AIDS crisis may be only just beginning, Datamonitor HIV analyst Dheeraj Khiytani investigates...

Published By Datamonitor
10 May 2002
CommentWire
CommentWire

Alteon: ALT-711 could generate $1.3 billion by 2010

Although the results of a US study show ISH continues to be under treated, this represents an opportunity for Alteon, which is developing ALT-711 specifically for ISH. Providing awareness of ISH is increased, Datamonitor forecasts that ALT-711 could generate sales of $1.3 billion by 2010, just three years after launch.<BR />

Published By Datamonitor
28 Mar 2003
CommentWire
CommentWire

Alteon: new trial for promising 'multi-modal' drug

Alteon's developmental drug ALT-711 looks promising for a broad range of age-related cardiovascular conditions. Its greatest advantage of the compound is that it is 'multi-modal' in action, potentially treating the underlying cause of several conditions in a single drug. If Alteon can find a strong marketing partner, the drug could prove highly successful.

Published By Datamonitor
17 Jul 2002
CommentWire
CommentWire

Alteon: sales of ALT-711 set to soar

Positive preliminary results indicate that Alteon's ALT-711 may be beneficial in treating patients with diastolic heart failure, as well as the underlying pathology of a number of diseases. ALT-711 is being targeted at areas of high unmet need with rapidly growing patient populations, a powerful combination that should see sales hit $1.3bn in 2010, just three years after launch.

Published By Datamonitor
23 Jan 2003
CommentWire
CommentWire

Alternative contraceptives: protection through numbers

The algorithm method can be effective, but requires couples to have an in-depth knowledge of the associated risks. It offers an alternative for women who are at high risk of medical problems if they take conventional hormone products. However, the development of low-dose hormone contraceptives offers a better solution for many women.<BR />

Published By Datamonitor
16 Nov 2001

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.